CN116059204A - 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法 - Google Patents

用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法 Download PDF

Info

Publication number
CN116059204A
CN116059204A CN202310081233.8A CN202310081233A CN116059204A CN 116059204 A CN116059204 A CN 116059204A CN 202310081233 A CN202310081233 A CN 202310081233A CN 116059204 A CN116059204 A CN 116059204A
Authority
CN
China
Prior art keywords
headache
dose
administered
migraine
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310081233.8A
Other languages
English (en)
Chinese (zh)
Inventor
S.奥罗拉
K.W.约翰逊
J.H.克雷格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN116059204A publication Critical patent/CN116059204A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202310081233.8A 2017-09-06 2018-08-30 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法 Pending CN116059204A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762554726P 2017-09-06 2017-09-06
US62/554726 2017-09-06
PCT/US2018/048730 WO2019050759A1 (en) 2017-09-06 2018-08-30 POLYTHERAPY OF LASMIDITAN AND CGRP ANTAGONIST FOR USE IN THE TREATMENT OF MIGRAINE
CN201880058157.6A CN111032044A (zh) 2017-09-06 2018-08-30 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880058157.6A Division CN111032044A (zh) 2017-09-06 2018-08-30 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法

Publications (1)

Publication Number Publication Date
CN116059204A true CN116059204A (zh) 2023-05-05

Family

ID=63529021

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310081233.8A Pending CN116059204A (zh) 2017-09-06 2018-08-30 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法
CN202310675929.3A Pending CN116509861A (zh) 2017-09-06 2018-08-30 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法
CN201880058157.6A Pending CN111032044A (zh) 2017-09-06 2018-08-30 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202310675929.3A Pending CN116509861A (zh) 2017-09-06 2018-08-30 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法
CN201880058157.6A Pending CN111032044A (zh) 2017-09-06 2018-08-30 用于治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法

Country Status (17)

Country Link
US (1) US20200268735A1 (https=)
EP (2) EP3678665A1 (https=)
JP (5) JP6922092B2 (https=)
KR (3) KR20230025945A (https=)
CN (3) CN116059204A (https=)
AU (1) AU2018329568B2 (https=)
BR (1) BR112020002077A2 (https=)
CA (1) CA3073996C (https=)
EA (1) EA202090457A1 (https=)
IL (2) IL314347A (https=)
MA (2) MA50073A (https=)
MX (2) MX2020002554A (https=)
MY (1) MY205182A (https=)
SG (1) SG11202001387WA (https=)
TW (1) TWI754772B (https=)
WO (1) WO2019050759A1 (https=)
ZA (1) ZA202000443B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2413933T5 (pl) 2009-04-02 2021-10-18 Colucid Pharmaceuticals, Inc. 2,4,6-trifluoro-N-[6-(1-metylopiperydyno-4-karbonylo)pirydyn-2-ylo]benzamid do leczenia migreny drogą doustną lub dożylną
TWI685505B (zh) * 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｇｒｐ活性化合物の錠剤製剤
KR20190075130A (ko) 2016-12-06 2019-06-28 코루시드 파마슈티컬즈 인코포레이티드 피리디노일피페리딘 5-ht1f 작용제에 관한 조성물 및 방법
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US20190374518A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
TWI826514B (zh) 2018-09-04 2023-12-21 美商美國禮來大藥廠 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
JP2022517433A (ja) * 2019-01-20 2022-03-08 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド 突出性の片頭痛を処置するためのｃｇｒｐアンタゴニスト
TWI776175B (zh) 2019-07-09 2022-09-01 美商美國禮來大藥廠 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
CN116270505A (zh) * 2021-12-20 2023-06-23 南京科默生物医药有限公司 含半琥珀酸拉司米地坦的口服固体制剂及其3d打印制备技术
JP7499538B1 (ja) 2023-03-29 2024-06-14 ロゴスサイエンス株式会社 慢性疼痛の治療、改善およびセルフケアシステム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20060142273A1 (en) * 2004-12-29 2006-06-29 Boehringer Ingelheim International Gmbh Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002353D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New use
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2005046659A2 (en) * 2003-11-12 2005-05-26 Nps Pharmaceuticals, Inc. Migraine treatments including isovaleramide compounds and serotonin agonists
US8697876B2 (en) * 2010-04-02 2014-04-15 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2018055574A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
RU2770066C2 (ru) * 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20060142273A1 (en) * 2004-12-29 2006-06-29 Boehringer Ingelheim International Gmbh Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIANCA RAFFAELLI ET AL: "The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine", EXPERT OPINION ON PHARMACOTHERAPY, vol. 18, no. 13, 10 August 2017 (2017-08-10) *
DIMOS D. MITSIKOSTAS ET AL: "New players in the preventive treatment of migraine", BMC MEDICINE, vol. 13, no. 279, 10 November 2015 (2015-11-10), pages 3 *

Also Published As

Publication number Publication date
JP7480261B2 (ja) 2024-05-09
KR20200036919A (ko) 2020-04-07
EP4397317A2 (en) 2024-07-10
EP3678665A1 (en) 2020-07-15
MY205182A (en) 2024-10-04
CN111032044A (zh) 2020-04-17
EP4397317A3 (en) 2024-10-16
EA202090457A1 (ru) 2020-06-10
KR20260027357A (ko) 2026-02-27
JP6922092B2 (ja) 2021-08-18
JP2023029872A (ja) 2023-03-07
JP7183355B2 (ja) 2022-12-05
US20200268735A1 (en) 2020-08-27
IL314347A (en) 2024-09-01
AU2018329568A1 (en) 2020-02-06
MA50073A (fr) 2020-07-15
JP7711255B2 (ja) 2025-07-22
TWI754772B (zh) 2022-02-11
JP2021176884A (ja) 2021-11-11
MA71474A (fr) 2025-04-30
MX2020002554A (es) 2020-07-13
CA3073996C (en) 2022-05-31
AU2018329568B2 (en) 2021-09-23
JP2020530861A (ja) 2020-10-29
WO2019050759A1 (en) 2019-03-14
SG11202001387WA (en) 2020-03-30
JP2024109585A (ja) 2024-08-14
ZA202000443B (en) 2022-07-27
TW201919624A (zh) 2019-06-01
JP2025165940A (ja) 2025-11-05
MX2023008760A (es) 2023-08-02
KR20230025945A (ko) 2023-02-23
IL273031A (en) 2020-04-30
CA3073996A1 (en) 2019-03-14
CN116509861A (zh) 2023-08-01
BR112020002077A2 (pt) 2020-07-28
NZ761634A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
JP7480261B2 (ja) 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法
JP6110367B2 (ja) ナロキソンを含む鼻腔内医薬剤形
US20250186422A1 (en) Treatment of migraine
Trivedi et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder
US20140221497A1 (en) Methods of Using Rapid-Onset Selective Serotonin Reuptake Inhibitors for Treating Sexual Dysfunction
JP2017128610A (ja) 併用ａｌｓ療法
Pirat et al. Ondansetron, orally disintegrating tablets versus intravenous injection for prevention of intrathecal morphine-induced nausea, vomiting, and pruritus in young males
Khan et al. Safety and efficacy of zavegepant in treating migraine: a systematic review
JP6885649B2 (ja) 統合失調症の治療のためのイロペリドン
HK40093158A (zh) 用於治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法
HK40097436A (zh) 用於治疗偏头痛的拉司米地坦与cgrp拮抗剂的组合疗法
EA042629B1 (ru) Комбинированная терапия ласмидитаном и антагонистом cgrp для применения в лечении мигрени
US20240398771A1 (en) Treatment of scleroderma and raynaud's syndrome
Hilas et al. Lofexidine: A Novel Treatment Option for Opioid Withdrawal Symptoms
US20240358693A1 (en) Methods of treating pain
WO2024196949A1 (en) Treatment of scleroderma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40093158

Country of ref document: HK